Skip to main navigation Skip to search Skip to main content

Synthesis and evaluation of 3-aroylindoles as anticancer agents: Metabolite approach

  • Yu Shan Wu
  • , Mohane Selvaraj Coumar
  • , Jang Yang Chang
  • , Hsu Yi Sun
  • , Fu Ming Kuo
  • , Ching Chuan Kuo
  • , Ying Jun Chen
  • , Chi Yen Chang
  • , Chia Ling Hsiao
  • , Jing Ping Liou
  • , Ching Ping Chen
  • , Hsien Tsung Yao
  • , Yi Kun Chiang
  • , Uan Kang Tan
  • , Chiung Tong Chen
  • , Chang Ying Chu
  • , Su Ying Wu
  • , Teng Kuang Yeh
  • , Chin Yu Lin
  • , Hsing Pang Hsieh

Research output: Contribution to journalArticlepeer-review

Abstract

BPR0L075 (2) is a potential anticancer drug candidate designed from Combretastatin A-4 (1) based on the bioisosterismprinciple.Metabolites of 2, proposed from in vitrohumanmicrosome studies,were synthesized, leading to the identification of metabolite-derived analogue 10 with 40-350 pM potency against various cancer cell lines. Insights gained from the major inactive metabolite of 2 led to the development of 29, with better pharmacokinetics and improved potency in the tumor xenograft model than 2.

Original languageEnglish
Pages (from-to)4941-4945
Number of pages5
JournalJournal of Medicinal Chemistry
Volume52
Issue number15
DOIs
Publication statusPublished - Aug 13 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Synthesis and evaluation of 3-aroylindoles as anticancer agents: Metabolite approach'. Together they form a unique fingerprint.

Cite this